PROCEPT BioRobotics Corporation

NasdaqGM PRCT

PROCEPT BioRobotics Corporation Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -100.06 M

PROCEPT BioRobotics Corporation Net Income is USD -100.06 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 8.13% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

PROCEPT BioRobotics Corporation Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -108.92 M, a -35.08% change year over year.
PROCEPT BioRobotics Corporation Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -80.63 M, a -41.99% change year over year.
PROCEPT BioRobotics Corporation Net Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -56.78 M.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqGM: PRCT

PROCEPT BioRobotics Corporation

CEO	Dr. Reza Zadno Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	900 Island Drive
Employees	626
Sector	Technology
Industries Robotics Biotechnology

Description

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

Key trends

Past 5 years